CD30 + T cell enriched primary cutaneous CD4 + small/medium sized pleomorphic T cell lymphoma: A distinct variant of indolent CD4 + T cell lymphoproliferative disease

Magro, Cynthia M.; Olson, Luke C.; Fulmer, Clifton G.

doi:10.1016/j.anndiagpath.2017.04.009

Cited by 17 publications

(24 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We did not observe positivity of CXCL‐13 in 18 stained patients. Yet, CD10 positivity was observed in some of our cases (11/15), which is not in line with previous researches describing that CD‐10 was often negative 6 . Most cases were positive in PD‐1 (12/17) and BCL‐6 (12/16), which was in accordance with previous results 7 .…”

Section: Discussionsupporting

confidence: 52%

See 1 more Smart Citation

Clinicopathological analysis of primary cutaneous CD4‐positive small/medium pleomorphic T‐cell lymphoproliferative disorder: a retrospective study of 22 patients

et al. 2020

View full text Add to dashboard Cite

Background Primary cutaneous CD4‐positive small/medium pleomorphic T‐cell lymphoproliferative disorder has been defined as a type of lymphoproliferative disorder with indolent clinical course and excellent prognosis, yet a precise diagnosis is still hard to reach. Methods A retrospective analysis of 22 patients including 16 females and six males was performed. Results The age of patients ranged from 5 to 79 years. The average age of all patients was 43.5, and the median age of all patients was 44.5. Two patients had multiple lesions, and others were presented with a solitary asymptomatic lesion. Besides general features, folliculotropism was observed in four cases. In addition to express CD3 and CD4, CD30 were positive to some extent. Some reactive cells could express CD8 and CD20. For follicular helper T‐cell markers, although CXCL‐13 was negative in the stained cases (18/18), the expression of PD‐1 (12/17), BCL‐6 (12/16) and CD10 (11/15) was observed in most cases. In addition, we performed T‐cell receptor (TCR) rearrangement on five patients, and all of them showed monoclonality. Nearly all patients had excellent prognosis. Conclusions Primary cutaneous CD4‐positive small/medium pleomorphic T‐cell lymphoproliferative disorder is complex. Some features like folliculotropism should also be noted. Besides, the expression of follicular helper T‐cell markers is not invariable. Moreover, CD8 positivity, Ki‐67 index, and lesion number were perhaps not absolute prognostic indicators. To reach a diagnosis of this rare entity, putting all the pieces together is important.

show abstract

Section: Discussionsupporting

confidence: 52%

“…Patient No. 18 showed scattered positivity of CD30 in tumor cells, which was in line with results of Magro et al ., who reported that a high percentage of CD30 positivity was a potential clue of regression 6 . Perhaps multiple lesions may not mean a bad prognosis, especially in patients with CD30 positivity.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological analysis of primary cutaneous CD4‐positive small/medium pleomorphic T‐cell lymphoproliferative disorder: a retrospective study of 22 patients

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Similar to cases reported in the past, our patient showed dense nodular infiltrates predominantly in the deep dermis and subcutis with a mixture of CD4+/PD1+ small‐ to medium‐sized pleomorphic T cells and B cells perivascularly and periadnexally . Predominance of CD4+ small‐ to medium‐sized pleomorphic T cells and B cells despite a small percentage (5%) of CD30+ large cells, monoclonal rearrangements, and its presence as a solitary nodule separates this lesion from other entities such as anaplastic large cell lymphoma (ALCL) and lymphoid hyperplasia . The existence of CD30+ cells, however, is interesting since only 24% of previous reported adult cases saw scattered CD30+ cells .…”

Section: Discussionsupporting

confidence: 86%

“…The existence of CD30+ cells, however, is interesting since only 24% of previous reported adult cases saw scattered CD30+ cells . Thus far, studies have shown that CD30+ staining T cells do not correlate to adverse prognostic factor of PCSM‐LPD lesions …”

Section: Discussionmentioning

confidence: 94%

Primary cutaneous CD4+ small‐ to medium‐sized pleomorphic T‐cell lymphoproliferative disorder in a pediatric patient successfully treated with low‐dose radiation

Kim

Aria

Wilmas

et al. 2018

Pediatric Dermatology

View full text Add to dashboard Cite

Primary cutaneous CD4+ small‐ to medium‐sized pleomorphic T‐cell lymphoproliferative disorder (PCSM‐LPD) is a rare and low‐grade form of cutaneous T‐cell proliferation with the average age of diagnosis of 54 years. Because of its rarity, the etiology or exact clinicopathology of PCSM‐LPD remains unclear, with < 10 pediatric cases reported. A 13‐year‐old boy presented to our clinic with a raised tumor with PCSM‐LPD histology and was successfully treated with ultra‐low‐dose radiation therapy. While no standard of care has been established for pediatric PCSM‐LPD, this report represents an example of achieving remission in a pediatric tumor with minimal potential for therapy‐related long‐term toxicity.

show abstract

“…A total of 18 studies identifying CD30 expression in primary cutaneous peripheral T-cell lymphoma, not otherwise specified (pcPTCL-NOS) and rare subtypes were found (Table 4). 31,59,[88][89][90][91][92][93][94][95][96][97][98][99][100][101][102][103] Two studies on pcPTCL-NOS with 170 patients, reported CD30 positive cells. CD30 negativity was described in one case of primary cutaneous acral CD8+ T-cell lymphoma (pcATCL).…”

Section: Primary Cutaneous Peripheral T-cell Lymphoma Not Otherwismentioning

confidence: 99%

A review ofCD30expression in cutaneous neoplasms

Kampa

Mitteldorf

2020

J Cutan Pathol

View full text Add to dashboard Cite

Background: The surface protein CD30 is a therapeutic target of monoclonal antibody therapy. Knowledge of the frequency of CD30 expression and its prognostic relevance is therefore interesting, not only in lymphoproliferative disorders (LPD) but also in solid tumors of the skin. Methods: A review was completed in PubMed for all published reports of CD30 expression in cutaneous lymphomas, mastocytosis, epithelial tumors and sarcomas from 1982 to April 2019. Only accessible articles in English and German were considered. Entities with an expected CD30 expression, such as CD30-positive LPD, were not evaluated. Results: The electronic research identified 1091 articles and a further 34 articles were obtained from manual bibliographic reference. Overall 91 articles were included that examined CD30 expression in various entities of cutaneous neoplasms and matched the inclusion criteria. Conclusion: Apart from cutaneous CD30-positive LPD, the best-studied group for CD30 expression was mycosis fungoides (MF). CD30 positivity was found in 32% of classical (patch and plaque stage) and in 59.4% cases of transformed MF. CD30 was also frequently expressed in cutaneous mastocytosis (96.5%). In solid tumors, some single reports describe CD30 expression by tumor cells, but CD30-reactive lymphocytes were frequently observed in the tumor microenvironment (TME), especially in keratoacanthoma (KA).

show abstract

CD30 + T cell enriched primary cutaneous CD4 + small/medium sized pleomorphic T cell lymphoma: A distinct variant of indolent CD4 + T cell lymphoproliferative disease

Cited by 17 publications

References 23 publications

Clinicopathological analysis of primary cutaneous CD4‐positive small/medium pleomorphic T‐cell lymphoproliferative disorder: a retrospective study of 22 patients

Clinicopathological analysis of primary cutaneous CD4‐positive small/medium pleomorphic T‐cell lymphoproliferative disorder: a retrospective study of 22 patients

Primary cutaneous CD4+ small‐ to medium‐sized pleomorphic T‐cell lymphoproliferative disorder in a pediatric patient successfully treated with low‐dose radiation

A review ofCD30expression in cutaneous neoplasms

Contact Info

Product

Resources

About